Sign In
Buy LEGN
$35.98
-0.300 (-0.83%)
At Close: Jun 03, 2026
Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT
05:15pm, Thursday, 22'nd May 2025
SOMERSET, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today that new data evaluating CARVYKTI® (cilta
LEGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Legend Biotech Corporation Shareholders Who Lost Money
07:30am, Thursday, 22'nd May 2025
NEW YORK, NY / ACCESS Newswire / May 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) co
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) co
Legend Biotech Corporation Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - LEGN
07:30am, Tuesday, 20'th May 2025
NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) co
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) co
LEGN ALERT: Levi & Korsinsky Investigates Legend Biotech Corporation for Possible Securities Fraud Violations
03:45pm, Thursday, 15'th May 2025
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Legend Biotech Corporation ("Legend Biotech Corporation") (NASDAQ:LEGN) co
Legend Biotech Corporation (LEGN) Q1 2025 Earnings Call Transcript
11:15am, Tuesday, 13'th May 2025
Legend Biotech Corporation (NASDAQ:LEGN ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - Chief Executive Officer Jess
Legend Biotech Reports First Quarter 2025 Results and Recent Highlights
07:00am, Tuesday, 13'th May 2025
SOMERSET, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2025 unaudited financial
What Makes Legend Biotech (LEGN) a New Buy Stock
01:05pm, Friday, 02'nd May 2025
Legend Biotech (LEGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Think Legend Biotech (LEGN) Could Surge 135.16%: Read This Before Placing a Bet
11:01am, Friday, 02'nd May 2025
The consensus price target hints at a 135.2% upside potential for Legend Biotech (LEGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings e
Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?
10:55am, Wednesday, 16'th Apr 2025
Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre
Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst
02:59pm, Tuesday, 08'th Apr 2025
With U.S. President Donald Trump's tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertain
Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript
12:06pm, Tuesday, 11'th Mar 2025
Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim
Legend Biotech Reports Fourth Quarter and Full Year 2024 Results and Recent Highlights
07:00am, Tuesday, 11'th Mar 2025
SOMERSET, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported financial results for the fourth quarter
Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)
03:40pm, Tuesday, 07'th Jan 2025
Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple
